PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IS ASSOCIATED WITH LP(A) IN TYPE 2 DIABETIC PATIENTS

被引：2
|
作者：
Nekaies, Y. [1 ]
Baudin, B. [2 ,3 ]
Sakly, M. [1 ]
Attia, N. [1 ]
机构：
[1] Univ Carthage, Fac Sci Bizerte, Res Unit Integrated Physiol UR11ES33, Bizerte, Tunisia
[2] Biol & Pathol Pole St Antoine Hosp, Dept Biochem, Paris, France
[3] Fac Pharm Chatenay Malabry, Paris, France
来源：
ATHEROSCLEROSIS | 2015年 / 241卷 / 01期
关键词：
D O I：
10.1016/j.atherosclerosis.2015.04.356
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS-0862
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [31] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS/LUPUS NEPHRITIS
    Fang, C.
    Luo, T.
    Lin, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1768 - 1769
  • [32] SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN NON-DIABETIC ASIANS WITH NEPHROTIC SYNDROME
    Lim, Cynthia
    Mok, Irene
    Tan, Hui Zhuan
    Teng, Esther W. L.
    Chue, Xiu Ping
    Ang, Wei Mian
    Chin, Yok Mooi
    Foo, Marjorie
    Choo, Jason
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 758 - 758
  • [33] Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
    Zhu, Yiming M.
    Anderson, Todd J.
    Sikdar, Khokan
    Fung, Marinda
    McQueen, Matthew J.
    Lonn, Eva M.
    Verma, Subodh
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (10) : 2254 - 2259
  • [34] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Sun, Huimin
    Meng, Wen
    Zhu, Jie
    Wang, Lu
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (06) : 643 - 658
  • [35] IDENTIFICATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FROM NATURAL PRODUCTS
    Hirata, Hiroshi
    Kontani, Ami
    Takazumi, Koji
    Segawa, Shuichi
    Tsuchiya, Youichi
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 1175 - 1175
  • [36] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
    Joseph, Lee
    Robinson, Jennifer G.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2015, 58 (01) : 19 - 31
  • [37] Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
    Sharotri, Vikas
    Collier, Daniel M.
    Olson, Diane R.
    Zhou, Ruifeng
    Snyder, Peter M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) : 19266 - 19274
  • [38] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Zhang, Lingling
    Song, Kangping
    Zhu, Mengting
    Shi, Jinling
    Zhang, Huijuan
    Xu, Liang
    Chen, Yingzhu
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (08) : 675 - 680
  • [39] Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
    Patel, Jeenal
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (04): : S76 - S82
  • [40] The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
    Marston, Nicholas A.
    Gurmu, Yared
    Melloni, Giorgio E. M.
    Bonaca, Marc
    Gencer, Baris
    Sever, Peter S.
    Pedersen, Terje R.
    Keech, Anthony C.
    Roselli, Carolina
    Lubitz, Steven A.
    Ellinor, Patrick T.
    O'Donoghue, Michelle L.
    Giugliano, Robert P.
    Ruff, Christian T.
    Sabatine, Marc S.
    CIRCULATION, 2020, 141 (20) : 1600 - 1607
12345